Tenapanor hydrochloride

盐酸替那帕诺

Report date: 2025/03/03 13:25:33
NMEFirst In Class

Base Information

Drug NameTenapanor hydrochloride
Drug Alias NameTenapanor替那帕诺盐酸替纳帕诺IbsrelaIBSRELA +[12] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSodium/hydrogen exchanger 3 inhibitors
TargetsSodium/hydrogen exchanger 3
Therapy Area/IndicationsChronic idiopathic constipationConstipationHyperphosphatemia +[9] 
Global Approved IndicationsConstipationHyperphosphatemiaRenal Insufficiency, Chronic +[4] 
Approved Indications in ChinaHyperphosphatemia
Original Approved Country/TerritoryUnited States
Original Approved Date2019/09/12
Country/TerritoryUnited StatesSlovakiaPoland +[6] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesArdelyx Inc
China Registration ClassN/A

Develop Information

Active CompaniesKyowa Kirin Co LtdArdelyx IncShanghai Fosun Pharmaceutical Industrial Development Co Ltd
Inactive CompaniesN/A
Active IndicationsChronic idiopathic constipationConstipationHyperphosphatemia +[8] 
Inactive IndicationsDiabetes Mellitus, Type 2

Other Information

ATC CodeA06AX
Related LinksWikipediaDrugBankKEGG